novel transcript, antisense to LUC7L2 (ENSG00000273391)

The entry "novel transcript, antisense to LUC7L2" (ENSG00000273391) does not refer to a canonical protein-coding therapeutic target such as a receptor, enzyme, transporter, or transcription factor. Rather, it is annotated as a "novel transcript" that is antisense to the LUC7L2 gene, meaning it is a transcribed RNA complementary to the protein-coding LUC7L2, but it is not a well-characterized functional gene or target itself. There is no evidence that this antisense transcript is considered a therapeutic target, nor is it associated with clear molecular function, disease relevance, or drug interaction. The gene product most frequently discussed in the literature is the LUC7L2 protein, a splicing factor with established roles in leukemia and immune regulation[1][2]. Use of the antisense "novel transcript" as a target is incorrect for therapeutic, biomarker, or pharmacological purposes.